Q-linea Ab · OMXSTO:QLINEA
Q-linea Ab — Q3 2021 Earnings Presentation
20 slides from Q-linea Ab's earnings presentation, Nov 4, 2021
Slide 1: Future Proof Healthcare – Presentation Q3(21)
FUTURE PROOF HEALTHCARE A sustainable healthcare for a new generation Presentation Q3(21) Jonas Jarvius, CEO Anders Lundin, CFO/IR
Slide 2: Disclaimer
Disclaimer DISCLAIMER THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS
Slide 3: Q-linea 3rd quarter – Introduction to the company
Headquarters, Marketing and demo lab, Consumable production in Uppsala Q-linea 3rd quarter Q-linea is developing disruptive solutions for faster Lead product ASTar® infectious disease diagnostics, first product targeting sepsis Introduction to the company 160 employees & consultants at third quarter
Slide 4: Sepsis – a global health crisis
Sepsis – a global health crisis Time to correct treatment critical for patient outcome 4
Slide 5: Why is improved infectious disease diagnostics important?
Why is improved infectious disease diagnostics important? Sepsis AMR Antimicrobial Resistance Leading cause of death in U.S. hospitals1) Has been presented as #1 hospitalization cost in the US with over $24bn “The biggest threat to mankind” yearly3) Rapid diagnostics would reduce Kills >500,000 peop
Slide 6: ASTar can provide up to 40 hours faster actionable results
Rapid AST & a broad antimicrobial panel matters: ASTar can provide up to 40 hours faster actionable results DAY 1 DAY 2 DAY 3 DAY 4 Plates are streaked CURRENT WORKFLOW Gram Susceptibility Patient to perform a Colony blood draw stain clean culture selection Determination (AST) Optimized Time to Bloo
Slide 7: Health economic benefits of 24 hour faster diagnostics
Health economic benefits of 24 hour faster diagnostics Less pressure for Cost savings Lower mortality resistance and superinfections Up to 25% Up to 40% ~$2,500 – $20,000 reduction of C. difficile lower mortality rates1) cost savings per patient3) infections2) ASTar can provide 24-40 hour faster dia
Slide 8: ASTar – a platform designed to save lifetimes
ASTar – a platform designed to save lifetimes Developed together with our future customers Easy to use Comprehensive • Fully automated • Large antibiotic panel • ~2 min hands-on time • Long concentration • Load-and go workflow ranges • Fastidious and non- fastidious bacteria Fast • Support additiona
Slide 9: Easy to use
Easy to use User friendly & 24/7 availability ASTar enables anyone at the lab to load sample anytime and enables lab personnel to do more in less time Click “start” Scan barcode Add sample Load AST disc Add sample barcode Click “Start run” Source: Company information and webpage 9
Slide 10: ASTar provides excellent performance
ASTar provides excellent performance Broad panel enabling actionable results Excellent and accurate data from the CE-IVD clinical study FDA and ISO requirements1,2) The ASTar® Instrument and ASTar® BC G- Kit offer the Essential agreement = Same MIC value as reference broadest combination of antimicr
Slide 11: High throughput and flexible solution
High throughput and flexible solution High throughput & flexible Our ambition was the most user friendly and capable system Up to 12 patient samples in parallel = Fully automatic Semi automatic Consumables stored at room temp and a small insert at -20°C. Compatible with small and large (e.g. urine)
Slide 12: Key highlights third quarter
Key highlights third quarter Commercial evaluation performed during the quarter with excellent results Thermo Fisher Scientific™ performed the evaluation supported by Q-linea Several European sites selected by Thermo Fisher Scientific to evaluate ASTar All results were compared to reference measurem
Slide 13: Key highlights third quarter – portable culture device
Key highlights third quarter Continued development of the portable culture device Fully functional prototypes has been extensively tested Average time to positivity is one hour or more faster compared to traditional culture cabinet – And you also save the entire travel time… Selection of contract ma
Slide 14: Key highlights after the period
Key highlights after the period US clinical study for ASTar enters next phase The reproducibility was started at three Swedish sites in October Last phase is to start prospective part of the study in US hospitals 14 14 Source: Company information.
Slide 15: Key highlights after the period
Key highlights after the period Thermo Fisher Scientific launched ASTar in Europe 7 October1 And Q-linea signed first evaluation contract for Sweden 15 October 1). https://www.prnewswire.co.uk/news-releases/thermo-fisher-scientific-and-q-linea-launch-astar-system- a-rapid-antimicrobial-susceptibilit
Slide 16: The effects of the Corona pandemic on Q-linea
The effects of the Corona pandemic on Q-linea Moving back to normal operation Finally, we are now all moving back to the new normal after the pandemic Our conclusion is that Q-linea and its personnel has managed the pandemic in a good way No identified spread within the company Rapid follow up and i
Slide 17: Income statement third quarter
Income statement third quarter Net sales in the third quarter amounted to SEK 1.1 million (0.0). Cost of Goods Sold and production costs SEK -3.1 (0) million Gross margin SEK -2,0 (0) million ; -182 (0) % Operating result totalled SEK -50.0 million (-50.0). The company reported a loss after tax of S
Slide 18: Balance sheet at the end of third quarter
Balance sheet at the end of third quarter Cash and cash equivalents amounted to SEK 21.6 million (10.1) Short-term investments in fixed-income funds SEK 181,2 million (165,7) and the current portion of non-current assets (listed bonds) SEK 26.3 million (131.0). Non-current assets, listed bonds SEK 2
Slide 19: Cash flow statement third quarter
Cash flow statement third quarter Cash flow from operating activities SEK -63.0 million (-46.7). Increase in cash outflow from operating activities mainly due to unfavorable changes in the working capital compared to the same quarter last year. Cash flow from investing activities SEK 36.5 million (2
Slide 20: Thank you
Looking forward to an exciting continuation of 2021 Q-linea wants to contribute to a healthier society by future- proofing a new generation of healthcare professionals, labs and hospitals. Thank you 20